TabsDetailsBasic DetailsDate Posted: Wednesday, June 5, 2019Status: CompleteMedical Product: angiotensin II receptor blocker (ARB), angiotensin-converting enzyme (ACE) inhibitor, azilsartan medoxomil, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartanDescription: This analysis estimates the rates of valsartan (contaminated and uncontaminated with N-nitrosodimethylamine (NDMA) or N-nitrosodiethylamine (NDEA)), angiotensin II receptor blocker (ARB), and angiotensin-converting enzyme (ACE) inhibitor use in the Sentinel Distributed Database (SDD). Data from January 1, 2000 to June 30, 2018 from 17 Data Partners contributing to the SDD were included in this report. This request was distributed on October 30, 2018. Read More Deliverables (1)Sentinel Modular Program Report: Use of Valsartan, Angiotensin II Receptor Blockers (ARB), and Angiotensin-Converting Enzyme (ACE) InhibitorsAdditional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2000 - June 30, 2018Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individualsData Sources: Sentinel Distributed Database (SDD)Related Links: 2019 ICPE Poster: Exposure to N-nitrosodimethylamine (NDMA)/N-nitrosodiethylamine (NDEA)-contaminated Angiotensin-II Receptor Blockers Products in the United States